PRKN and neuroblastoma: Using human-induced pluripotent stem cell (hiPSC)-derived neuronal cell models from an unaffected 86-year-old carrier, genome-edited control lines, neuroblastoma cell lines, and in silico prediction, we investigated the underlying mechanism.<h4>Results</h4>Patients with PRKN Exon 2 deletions showed a later age at onset compared with carriers of other pathogenic variants.